Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 1:14:731-735.
doi: 10.2147/CLEP.S364692. eCollection 2022.

Identifying Individual Medications Affecting Pulmonary Outcomes When Multiple Medications are Present

Yisha Li  1 , Ran Dai  2 , Yeongjin Gwon  2 , Stephen I Rennard  3 , Barry J Make  4 , Dinah Foer  5 , Matthew J Strand  4 , Erin Austin  6 , Kendra A Young  1 , John E Hokanson  1 , Katherine A Pratte  7 , Rebecca Conway  1 , Gregory L Kinney  1 ; COPDGene investigators
Affiliations

Identifying Individual Medications Affecting Pulmonary Outcomes When Multiple Medications are Present

Yisha Li et al. Clin Epidemiol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

In the last three years, Dr. Stephen I. Rennard has received fees for consulting from Alpha 1 Foundation, Berfenbio, GlaxoSmithKline, Verona, Boehringer Ingelheim, Novo Ventures and Sanofi. He is also the Medical Director for the Alpha 1 Foundation Therapeutic Development Network. From 2015 to 2019, he was an employee of AstraZeneca and received shares as part of his compensation. Over the last three years Dr. Barry Make reports grants from NHLBI, American Lung Association, Department of Defense, Pearl Research, Circassia, GlaxoSmithKline, and AstraZeneca; advisory board fees from GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Mt. Sinai, Web MD, Novartis, American College of Chest Physicians, Projects in Knowledge, Novartis, personal fees from American College of Chest Physicians, personal fees from Projects in Knowledge, Mylan, Eastern Pulmonary Society, Wolters Kluwer Health (Up-To-Date), Optimum Patient Care Global Limited, Integritas Communications, Quintiles, University of Wisconsin, Third Pole, and Phillips; consulting fees from AstraZeneca; Data Safety and Monitoring Board fees from NHLBI, Takeda and Spiration. Dr Kendra A Young reports grants from NIH, during the conduct of the study. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
All selected medications meeting the cutoff criteria for one or more pulmonary outcomes. Figure 1 shows all 7 concurrent medications strongly associated (frequency of selection stability >0.5 for at least one outcome) with Emphysema (black bar), FEV1 (green bar), FEV1_pp (yellow bar) and FVC (blue bar) progression. The x-axis of Figure 1 is frequency of stability selection experiment using the Knockoff variable selection procedure. Higher frequency from the stability selection means a particular variable is more likely to be a true signal.
See this image and copyright information in PMC

References

    1. Negewo NA, Gibson PG, McDonald VM. COPD and its comorbidities: impact, measurement and mechanisms. Respirology. 2015;20(8):1160–1171. doi:10.1111/resp.12642 - DOI - PubMed
    1. Barber RF, Candès EJ. Controlling the false discovery rate via knockoffs. Ann Stat. 2015;43(5):2055–2085, 2031. doi:10.1214/15-AOS1337 - DOI
    1. Dai Ran ZC. Multiple testing for composite null with FDR control guarantee. arXiv preprint arXiv. 2021. doi:10.48550/arXiv.2106.12719 - DOI
    1. Regan EA, Hokanson JE, Murphy JR, et al. Genetic epidemiology of COPD (COPDGene) study design. Copd. 2010;7(1):32–43. doi:10.3109/15412550903499522 - DOI - PMC - PubMed
    1. Li Y, Ragland M, Austin E, et al. Co-morbidity patterns identified using latent class analysis of medications predict all-cause mortality independent of other known risk factors: the COPDGene(®) Study. Clin Epidemiol. 2020;12:1171–1181. doi:10.2147/CLEP.S279075 - DOI - PMC - PubMed

LinkOut - more resources